Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Current Liabilities (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Total Current Liabilities for 7 consecutive years, with $58.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 27.66% to $58.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.8 million through Dec 2025, up 27.66% year-over-year, with the annual reading at $58.8 million for FY2025, 27.66% up from the prior year.
  • Total Current Liabilities hit $58.8 million in Q4 2025 for IDEAYA Biosciences, down from $64.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $64.5 million in Q3 2025 to a low of $24.9 million in Q3 2023.
  • Historically, Total Current Liabilities has averaged $41.2 million across 5 years, with a median of $39.6 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: soared 391.82% in 2021 and later tumbled 56.38% in 2023.
  • Year by year, Total Current Liabilities stood at $45.2 million in 2021, then dropped by 29.76% to $31.7 million in 2022, then decreased by 14.56% to $27.1 million in 2023, then skyrocketed by 70.0% to $46.1 million in 2024, then grew by 27.66% to $58.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for IDYA at $58.8 million in Q4 2025, $64.5 million in Q3 2025, and $55.3 million in Q2 2025.